Polyethylene glycol (PEG) conjugation  (PEGylation) has become an established approach for modifying the pharmacokinetic properties of therapeutic proteins. Among the well-known examples is pegfilgrastim, a long-acting form of recombinant human granulocyte colony-stimulating factor (G-CSF) developed through the covalent attachment of a 20 kDa monomethoxy polyethylene glycol (mPEG) chain to filgrastim.

The development of pegfilgrastim illustrates how the selection of a suitable PEG molecular weight and conjugation site can influence the behavior of a protein therapeutic. Rather than changing the fundamental biological function of G-CSF, PEGylation modifies the physicochemical characteristics of the protein, helping extend its circulation time and duration of action.

This article examines the principles of G-CSF PEGylation, the chemistry behind N-terminal modification, the role of 20 kDa mPEG-propionaldehyde, and the emerging conjugation strategies.
​

What Is PEGylated G-CSF?

Granulocyte colony-stimulating factor (G-CSF) is an essential hematopoietic cytokine that regulates the proliferation, differentiation, maturation, and survival of neutrophil precursor cells. Recombinant human G-CSF (filgrastim) is widely used in oncology to prevent chemotherapy-induced neutropenia.

Unmodified filgrastim has a molecular mass of approximately 18.8 kDa and a compact hydrodynamic radius, which results in rapid elimination from the body via renal filtration and a short half-life of 3.5 hours. This short circulation time necessitates daily subcutaneous injections throughout each chemotherapy cycle to maintain therapeutic plasma concentrations, presenting compliance challenges and fluctuating serum drug levels.

Pegfilgrastim was developed to extend the duration of G-CSF activity. It is produced by covalently attaching one approximately 20 kDa monomethoxy PEG molecule to the N-terminal methionine residue of filgrastim. The addition of a PEG chain dramatically increases the hydrodynamic size of the drug and thus excludes it from glomerular filtration. Consequently, neutrophil-mediated clearance predominates in elimination of the drug. This extends the median serum half-life of pegfilgrastim to 42 hours, compared with between 3.5 hours for Filgrastim.

Pegfilgrastim retains the same biological activity as filgrastim, and binds to the same G-CSF receptor, stimulating the proliferation, differentiation and activation of neutrophils. Once-per-chemotherapy cycle administration of pegfilgrastim reduces the duration of severe neutropenia as effectively as daily treatment with filgrastim.
 

How Does N-Terminal PEGylation Work in Pegfilgrastim?

Proteins contain several types of reactive functional groups, including primary amino groups on the N-terminus and the side chains of lysine residues.

Conventional PEGylation using amine-reactive reagents can potentially produce multiple conjugation products when several accessible amino groups are present. These products may differ in the number and location of attached PEG chains. 

N-terminal PEGylation offers an alternative approach to improving conjugation selectivity. One of the best examples of the efficiency of such conjugation is the approval of Pegfilgrastim (Neulasta®) .

In pegfilgrastim, a single 20 kDa mPEG chain (methoxy PEG aldehyde) is covalently attached to this N-terminal methionine via site-directed reductive alkylation at slightly acidic pH (4.5-4.8), giving the conjugate an average molecular weight of approximately 39 kDa.

This N-terminal modification works by taking advantage of the difference in pKa between the protein's N-terminal alpha-amino group (pKa≈7.8) and the epsilon-amino groups of lysine residues (pKa=10.1) . Under appropriately controlled mildly acidic conditions, the lysine amine group is predominantly protonated and therefore unable to react with the aldehyde group, making the free amine on the N-terminus the only site for modification. Chemoselective targeting of the N terminal α-amine represents an asset to obtain reproducible well-defined protein monoconjugates with more uniform PK/PD properties.
 

Why Is 20 kDa PEG–aldehyde Used?

20 kDa PEG–aldehyde combines a defined functional end group with a PEG chain of a selected molecular weight, making it suitable for reductive amination-based protein modification.

Methoxy group: Caps one end of the PEG chain and limits unwanted reactions at that terminus.
Propionaldehyde group: Provides the reactive aldehyde functionality needed for N-terminal reductive alkylation.

The selection of PEG molecular weight is closely related to the desired properties of the resulting protein conjugate. In pegfilgrastim, the 20 kDa PEG chain increases the hydrodynamic size of filgrastim. This reduces renal filtration and contributes to the prolonged circulation of the conjugate.

However, PEG molecular weight is not simply a matter of choosing the largest available polymer.

Increasing PEG size can also influence:

• ● Accessibility of the protein's receptor-binding region.
• ● Steric interactions between the PEG chain and protein surface.
• ● Hydrodynamic radius and molecular distribution.
• ● Conjugation efficiency and purification behavior.
• ● Overall biological activity.

Therefore, PEG molecular weight should be selected according to the properties of the target protein and the intended application.
 

Status of Biosimilars and Derivatives

Following the patent expiration of the reference product Neulasta, eight pegfilgrastim biosimilars had been approved globally by November 2026. All adhere to the conventional N-terminal 20kD PEGylation route, including Fulphila (pegfilgrastim-jmdb), Udenyca (pegfilgrastim-cbqv), Ziextenzo (pegfilgrastim-bmez), Nyvepria (pegfilgrastim-apgf), Fylnetra (pegfilgrastim-pbbk), Stimufend (pegfilgrastim-fpgk), Armlupeg (pegfilgrastim-unne), and Ennumo (pegfilgrastim-pccg).

In parallel, developers have investigated modified long-acting derivatives such as Empegfilgrastim (under investigation in clinical trial NCT01569087). This candidate utilizes a higher-molecular-weight 30kDa linear PEG chain conjugated at the N-terminus to further increase the hydrodynamic radius and extend plasma residence time in vivo.
 

Limitations of the N-Terminal PEGylation Route

Despite the robust commercial success of the mPEG-propionaldehyde 20K platform, protein chemistry and industrial bioprocessing reveal several inherent drawbacks:

• ● Structural Heterogeneity and Byproduct Control: Even under tightly regulated acidic pH conditions, the nucleophilicity of lysine side-chain amino groups cannot be entirely suppressed. Consequently, the reaction mixture inevitably contains minor amounts of lysine-modified positional isomers (such as Lys17, Lys23, Lys35, or Lys41 adducts) alongside multi-PEGylated byproducts. This heterogeneity complicates downstream purification and diminishes final manufacturing yields.
• ● Receptor Steric Hindrance and Activity Loss: Structural and crystallographic data demonstrate that G-CSF engagement with the G-CSF receptor (G-CSF-R) involves four principal alpha-helical bundles. Because the N-terminal region lies close to this binding interface, attachment of a bulky 20 kDa flexible PEG chain introduces significant steric hindrance. This spatial obstruction drastically reduces the in vitro receptor binding affinity and biological potency of pegfilgrastim to unmodified filgrastim.

Different PEGylation Strategies for Long-Acting G-CSF

N-terminal PEGylation is not the only approach used to extend G-CSF activity. Different molecular designs can achieve longer exposure through different mechanisms.

Lipegfilgrastim: Site-Specific GlycoPEGylation

Lipegfilgrastim (Lonquex®, Teva Biopharmaceuticals) uses a different strategy, which has been licensed by EMA in 2013, and marketed in Germany. Rather than attaching PEG directly to the protein's N-terminal amino group, a 20 kDa PEG chain is attached enzymatically through a carbohydrate-based linker at Thr134.

This approach is known as glycoPEGylation. The method involves a sequence of enzymatic GalNAc O-glycosylation at specific S and T residues of recombinant aglycosylated proteins, followed by enzymatic transfer of Gal and NeuNAc bearing a 20 kDa PEG to the initially introduced GalNAc.

Efbemalenograstim Alfa: An Fc-Fusion Approach

Not every long-acting G-CSF product is PEGylated.

Efbemalenograstim alfa, marketed as Ryzneuta, is a novel Fc fusion protein, with the construct of G-CSF fused to an immunoglobulin (Ig) G2-Fc fragment via a 16 amino acid peptide linker, with decreased clearance and prolonged half-life of about 46 h.

This is a protein-fusion strategy, not PEGylation. It is useful to distinguish these approaches when comparing long-acting G-CSF technologies.

Maleimide PEG-based Site-specific PEGylation

In a 2020 study, researchers engineered cysteine variants of G-CSF to facilitate the maleimide PEG-based site-specific PEGylation that leads to a highly homogenous PEGylated product. The research has demonstrated:

Conjugating a 20 kDa thiol-reactive maleimide-PEG to the Cys2 G-CSF variant achieved leukocyte proliferative activity comparable to that of commercial aldehyde-PEG conjugates in murine neutropenia models.

Evaluating higher-molecular-weight polymers revealed that conjugating 30 kDa or 40 kDa PEGs to the cysteine variant significantly prolonged leukocyte proliferation compared to the 20 kDa version. Even a half-dose of the 40 kDa PEG-conjugated variant demonstrated markedly extended biological activity relative to the standard 20 kDa commercial comparator.

Finally, administering the 40 kDa PEG-variant on the day of cyclophosphamide dosing effectively mitigated chemotherapy-induced neutropenia by accelerating leukocyte recovery in vivo.
 

Conclusion

The development of pegfilgrastim illustrates how PEG chemistry can be used to modify the pharmacokinetic properties of therapeutic proteins while retaining their underlying biological function. Its N-terminal conjugation strategy, based on a single 20 kDa mPEG chain attached to filgrastim through reductive alkylation, established an important application for aldehyde-functionalized PEG.

Other approaches, including glycoPEGylation, Fc-Fusion and maleimide PEG-based site-specific PEGylation, demonstrate the broader possibilities of long acting G-CSF modification.

For biopharmaceutical researchers, selecting the right PEG reagent involves considering molecular weight, polymer architecture, terminal functionality, purity and batch consistency together with the characteristics of the target protein. As protein conjugation technologies continue to develop, reliable functionalized PEG materials and appropriate analytical characterization remain essential components of reproducible PEGylation research and process development.
 

About Biopharma PEG

Biopharma PEG supplies functionalized PEG derivatives for pharmaceutical research, drug delivery and bioconjugation applications. Our PEG portfolio includes a range of molecular weights, polymer architectures and terminal functional groups to support different protein modification and conjugation requirements.

For researchers working on PEGylated proteins, relevant materials include:

• ● mPEG-Aldehyde: For reductive amination and N-terminal protein PEGylation research.
• ● Maleimide PEG: For thiol-directed protein conjugation and cysteine modification.
• ● NHS-PEG: For amine-reactive protein and biomolecule modification.
• ● Other functionalized PEG derivatives: Including amino, carboxyl, azide and alkyne PEGs for different conjugation strategies.

We also support custom PEG synthesis for projects requiring specific molecular weights, terminal groups or polymer architectures. Contact Biopharma PEG to discuss PEG specifications, available molecular weight options, analytical documentation and custom synthesis requirements.

References:
[1] Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des. 2004;10(11):1235-44. doi: 10.2174/1381612043452613. PMID: 15078138.
[2] A.Rondon, S. Mahri, F. Morales-Yanez, M. Dumoulin, R. Vanbever, Protein Engineering Strategies for Improved Pharmacokinetics. Adv. Funct. Mater. 2021, 31, 2101633. https://doi.org/10.1002/adfm.202101633
[3] Qi-Ying Hu, Francesco Berti, Roberto Adamo; Towards the next generation of biomedicines by site-selective conjugation. Chem. Soc. Rev. 2016; 45 (6): 1691–1719. https://doi.org/10.1039/c4cs00388h
[4] Guariglia R, Martorelli MC, Lerose R, Telesca D, Milella MR, Musto P. Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients. Biologics. 2016 Jan 22;10:1-8. doi: 10.2147/BTT.S58597. PMID: 26858523; PMCID: PMC4730998.
[5] Ma M, Di J, Wang C, Xie Y, Cui F, Zhai Y, Zhu S, Gao J. Site-specific PEGylation of proteins: Insights into structural and functional changes. Acta Pharm Sin B. 2025 Dec;15(12):6253-6273. doi: 10.1016/j.apsb.2025.10.014. Epub 2025 Oct 22. PMID: 41477338; PMCID: PMC12750161.
[6] Glaspy J, Bondarenko I, Burdaeva O, Chen J, Rutty D, Li R, Wang S, Hou Q, Li S. Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial. Support Care Cancer. 2023 Dec 16;32(1):34. doi: 10.1007/s00520-023-08176-6. PMID: 38103088; PMCID: PMC10725375.
[7] Kumari M, Sahni G and Datta S (2020) Development of Site-Specific PEGylated Granulocyte Colony Stimulating Factor With Prolonged Biological Activity. Front. Bioeng. Biotechnol. 8:572077. doi: 10.3389/fbioe.2020.572077